Pharmacological management of gastrointestinal stromal tumours: An update on the role of sunitinib

Annals of Oncology

Volumn 21, Issue 2, 2009, Pages 208-215

  Blay, J Y ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b EORTC DATA CENTER   (Belgium)

Author keywords

Adverse events; Efficacy; Gastrointestinal stromal tumours; KIT; Resistance; Sunitinib malate

Indexed keywords

IMATINIB; INTERLEUKIN 6; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; BLOOD ANALYSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EVENING DOSAGE; EXON; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; GLOSSODYNIA; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INDIVIDUALIZATION; KIDNEY CARCINOMA; MORNING DOSAGE; MOUTH PAIN; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; TASTE DISORDER; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WILD TYPE;

EID: 77949535841     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp291     Document Type: Review

References (47)

1. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology 2006; 48: 83-96.
2. Reddy P, Boci K, Charbonneau C. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours. J Clin Pharm Ther 2007; 32: 557-565.
3. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
4. National Institute for Clinical Excellence. NICE Technology Appraisal 86: Imatinib for the Treatment of Unresectable and/or Metastatic Gastro-intestinal Stromal Tumours, 2004. London: National Institute for Clinical Excellence 2004; http://www.nice.org.uk/TA086guidance (11 May 2008, date last accessed).
5. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005; 12: 44-56.
6. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710.
7. Medeiros F, Corless CL, Duensing A et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28: 889-894.
8. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004; 202: 430-438.
9. Casali PG, Jost L, Reichardt P et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii35-ii38.
10. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
11. Van Glabbeke M, Verweij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804.
12. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
13. Novartis Pharmaceuticals UK Ltd. Glivec Tablets, eSPC. 2007; http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=15014 (11 August 2008, date last accessed).
14. Pfizer Inc. SUTENT, Summary of Product Characteristics. February 2009.
15. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
16. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91: 4070-4076.
17. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
18. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
19. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
20. Pfizer Inc. Protocol No. RTKC-0511-013: A Phase I/II Study of SU011248 in the Treatment of Patients with Malignant Gastrointestinal Stromal Tumor (GIST) who are Intolerant of, or with Disease Progressing on, Imatinib Mesylate (Gleevec™). 2007; http://www.clinicalstudyresults.org/drugdetails/?company_id=2&;inn_name_id=402&indication_id=1044&sort=c.company_name&page=1&drug_id=2331 (9 September 2008, date last accessed).
21. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
22. Demetri GD, Huang X, Garrett CR et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure [poster discussion]. J Clin Oncol 2008; 26(15S): 559s (Abstr 10524).
23. Robins JM, Tsiatis AA. Correcting for non-compliance in randomised trials using rank-preserving structural failure time models. Commun Stat: Theory Methods 1991; 20: 2609-2631.
24. Blackstein M, Huang X, Demetri GD et al. Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in patients with advanced GIST receiving sunitinib (SU). In Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, FL January 25-27, 2008 (Abstr 19) (Poster).
25. Reichardt P, Kang Y, Ruka W et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST [poster presentation]. J Clin Oncol 2008; 26(15S): 565s (Abstr 10548).
26. George S, Blay JY, Casali PG et al. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis [poster presentation]. J Clin Oncol 2008; 26(15S): 566s (Abstr 10554).
27. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
28. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib malate in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359.
29. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
30. Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774.
31. Prenen H, Cools J, Mentens N et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622-2627.
32. Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-4190.
33. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.
34. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Clinical Practice Guidelines in Oncology™: Soft Tissue Sarcoma V.2.2008 National Comprehensive Cancer Network 2008 update. http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf (11 September 2008, date last accessed).
35. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
36. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660-664.
37. Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92: 3531-3534.
38. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
39. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
40. Pfizer Inc. SUTENT® (Sunitinib) eSPC. 2008; http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=18531 (11 September 2008, date last accessed).
41. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83.
42. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72(3): 424-430.
43. Houk BE, Bello CL, Michaelson MD et al. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC) [oral]. Eur J Cancer Suppl 2007; 5(4): 300 (Abstr 4505).
44. Demetri GD, Casali PG, Bello C. A population pharmacokinetic/pharmacodynamic (PK/PD) meta-analysis of sunitinib in patients with gastrointestinal stromal tumour. In Presented at the 19th International Congress on Anti-Cancer Treatment (ICACT), 5-8 February, 2008, Paris, France.
45. Judson I, Ma P, Peng B et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379-386.
46. Gambacorti-Passerini C, Zucchetti M, Russo D et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9: 625-632.
47. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25(9): 1107-1113.